非酒精性脂肪性肝病与心力衰竭的关系及治疗进展

    Association between non-alcoholic fatty liver disease and heart failure and progress in therapies

    • 摘要: 非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是目前全球范围内最常见的慢性肝病,约影响着全球30%的成年人。该病症会导致各种肝脏和肝外疾病的不良事件,并因此占用大量的医疗资源。心血管疾病(cardiovascular disease,CVD)是NAFLD患者的主要死亡原因,其中心力衰竭(heart failure,HF)是近年来全球发病率增长最快的心血管疾病。多项研究已经证实,非酒精性脂肪性肝病与HF的发生发展具有密切的联系。通过深入探讨非酒精性脂肪性肝病与HF的相关性、可能的作用机制以及治疗方案,我们可以更全面地理解这两种疾病的相互关系,并提供有效的治疗建议,包括改变生活方式、钠-葡萄糖协同转运蛋白2 (sodium-dependent glucose transporters 2,SGLT-2)抑制剂、GLP-1 受体激动剂(glucagon-like peptide-1 receptor agonist, GLP-1RA)、他汀类药物、减肥手术等应用。未来还需要更多的临床研究来进一步明确两者的关系和作用机制,为临床治疗提供更多有价值的参考。

       

      Abstract: Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent cause of chronic liver disease globally, affecting approximately 30% of adults worldwide. NAFLD leads to a significant number of adverse effects related to hepatic and extrahepatic diseases, burdening healthcare systems with significant utilization of medical resources. Cardiovascular disease (CVD) is the main cause of mortality in patients with NAFLD. In recent years, the incidence rate of heart failure (HF) has become the fastest growing cardiovascular disease in the world. Multiple studies have shown that non-alcoholic fatty liver disease is closely related to the occurrence and development of heart failure. This article aims to explore the correlation, possible mechanisms and treatment options between non-alcoholic fatty liver disease and heart failure, in order to gain a deeper understanding of the correlation between non-alcoholic liver disease and heart failure and to provide reference for better research on therapy options.

       

    /

    返回文章
    返回